Brief: Cyclo Therapeutics Forms Committee To Advise On Phase 3 Trial For Trappsol Cyclo
03/02/2022 13:23
Feb 3 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ANNOUNCES FORMATION OF GLOBAL STEERING
COMMITTEE COMPRISED OF LEADING EXPERTS TO ADVISE ON THE GLOBAL
PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR TRAPPSOL® CYCLO™ IN
NIEMANN-PICK DISEASE TYPE C
* CYCLO THERAPEUTICS - PIVOTAL PHASE 3 STUDY,
TRANSPORTNPC™,
ONGOING WITH GLOBAL SITE ACTIVATION AND PATIENT ENROLLMENT
UNDERWAY
* CYCLO- DATA SEEN TO-DATE GIVE SUPPORT FOR CAPACITY OF
TRAPPSOL(®) CYCLO™ TO STABILIZE DISEASE PROGRESSION WITH
HOME-BASED INTRAVENOUS INFUSIONS IN NPC
Source text for Eikon: ID:nBw3g0g5qa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug